Biostem Technologies Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
26
- Stock Symbol
-
BSEM
- Investments
-
8
- Share Price
-
$13.74
- (As of Friday Closing)
Biostem Technologies General Information
Description
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.
Contact Information
Website
www.biostemtechnologies.comCorporate Office
- 2836 Center Port Circle
- Pompano Beach, FL 33064
- United States
Corporate Office
- 2836 Center Port Circle
- Pompano Beach, FL 33064
- United States
Biostem Technologies Stock Performance
As of 20-Jun-2025, Biostem Technologies’s stock price is $13.74. Its current market cap is $229M with 16.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.74 | $13.11 | $6.95 - $28.26 | $229M | 16.7M | 68.3K | -$0.57 |
Biostem Technologies Financials Summary
As of 31-Dec-2023, Biostem Technologies has a trailing 12-month revenue of $16.7M.
|
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 85,511 | 85,511 | 32,485 | 15,390 |
| Revenue | 16,685 | 16,685 | 6,875 | 4,341 |
| EBITDA | (6,933) | (6,933) | (6,541) | (602) |
| Net Income | (7,863) | (7,863) | (7,193) | (1,445) |
| Total Assets | 14,560 | 14,560 | 3,466 | 2,672 |
| Total Debt | 4,724 | 4,724 | 5,089 | 4,831 |
Biostem Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biostem Technologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biostem Technologies Patents
Biostem Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240408148-A1 | Human umbilical compositions and methods for dermal application | Pending | 07-Jun-2023 | ||
| US-20250186506-A1 | Human umbilical cord composition for treatment of peyronie's disease | Pending | 11-Jan-2023 | ||
| US-20240226181-A1 | Human umbilical cord composition for treatment of peyronie's disease | Pending | 11-Jan-2023 | ||
| EP-4561595-A2 | Human umbilical cord compositions and methods for intra-articular therapy | Pending | 26-Jul-2022 | ||
| AU-2023315778-A1 | Human umbilical cord compositions and methods for intra-articular therapy | Pending | 26-Jul-2022 | A61K35/51 |
Biostem Technologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biostem Technologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biostem Technologies Investments & Acquisitions (8)
Biostem Technologies’s most recent deal was a Merger/Acquisition with ProgenaCare Global. The deal was made on 20-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ProgenaCare Global | 20-Nov-2024 | Merger/Acquisition | Biotechnology | ||
| Auxocell Laboratories | 27-Feb-2023 | Merger/Acquisition | Diagnostic Equipment | ||
| Grupo Impulso De Incentivacion Para Nuevas Tecnologías | 26-Feb-2018 | Merger/Acquisition | Biotechnology | ||
| Granisol | 22-Aug-2016 | Corporate Asset Purchase | Buildings and Property | ||
| TEN Health | 18-May-2016 | Merger/Acquisition | Clinics/Outpatient Services |
Biostem Technologies Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Auxocell Laboratories | Cambridge, MA | 2008 |
Biostem Technologies FAQs
-
When was Biostem Technologies founded?
Biostem Technologies was founded in 2014.
-
Where is Biostem Technologies headquartered?
Biostem Technologies is headquartered in Pompano Beach, FL.
-
What is the size of Biostem Technologies?
Biostem Technologies has 26 total employees.
-
What industry is Biostem Technologies in?
Biostem Technologies’s primary industry is Biotechnology.
-
Is Biostem Technologies a private or public company?
Biostem Technologies is a Public company.
-
What is Biostem Technologies’s stock symbol?
The ticker symbol for Biostem Technologies is BSEM.
-
What is the current stock price of Biostem Technologies?
As of 20-Jun-2025 the stock price of Biostem Technologies is $13.74.
-
What is the current market cap of Biostem Technologies?
The current market capitalization of Biostem Technologies is $229M.
-
What is Biostem Technologies’s current revenue?
The trailing twelve month revenue for Biostem Technologies is $16.7M.
-
What is Biostem Technologies’s annual earnings per share (EPS)?
Biostem Technologies’s EPS for 12 months was -$0.57.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
